Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie's disease and erectile dysfunction: Results from a prospective randomized trial

International Journal of Andrology

Volumn 35, Issue 2, 2012, Pages 190-195

  Palmieri, A ^a   Imbimbo, C ^a   Creta, M ^a   Verze, P ^a   Fusco, F ^a   Mirone, V ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Extracorporeal shock wave therapy; Peyronie's disease; Tadalafil

Indexed keywords

TADALAFIL;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; ERECTILE DYSFUNCTION; EXTRACORPOREAL LITHOTRIPSY; FOLLOW UP; HUMAN; INTERNATIONAL INDEX OF ERECTILE FUNCTION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PENIS ERECTION; PEYRONIE DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; VISUAL ANALOG SCALE;

ADULT; AGED; CARBOLINES; COMBINED MODALITY THERAPY; ERECTILE DYSFUNCTION; HIGH-ENERGY SHOCK WAVES; HUMANS; MALE; MIDDLE AGED; PAIN; PENILE ERECTION; PENILE INDURATION; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 84858291117     PISSN: 01056263     EISSN: 13652605     Source Type: Journal    
DOI: 10.1111/j.1365-2605.2011.01226.x     Document Type: Article

References (25)

1. Bivalacqua TJ, Purohit SK & Hellstrom WJ. (2000) Peyronie's disease: advances in basic science and pathophysiology. Curr Urol Rep 1, 297-301.
2. Claro JA, Passerotti CC, Figueiredo Neto AC, Nardozza A Jr, Ortiz V & Srougi M. (2004) An alternative non-invasive treatment for Peyronie's disease. Int Braz J Urol 30, 199-204.
3. Dohle G. (2006) Peyronie's Disease: Can We Prevent Disease Progression? Eur Urol 49, 946-947.
4. Donatucci CF, Wong DG, Giuliano F, Glina S, Dowsett SA, Watts S & Sorsaburu S. (2008) Efficacy and safety of tadalafil once daily: considerations for the practical application of a daily dosing option. Curr Med Res Opin 24, 3383-3392.
5. Ferrini MG, Kovanecz I, Nolazco G, Rajfer J & Gonzalez-Cadavid NF. (2006) Effects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie's disease. BJU Int 97, 625-633.
6. Gonzalez-Cadavid NF & Rajfer J. (2009) Experimental models of Peyronie's disease. Implications for new therapiesx. J Sex Med 6, 303-313.
7. Gonzalez-Cadavid NF & Rajfer J. (2010) Treatment of Peyronie's disease with PDE5 inhibitors: an antifibrotic strategy. Nat Rev Urol 7, 215-221.
8. Hauck EW, Hauptmann A, Bschleipfer T, Schmelz HU, Altinkilic BM & Weidner W. (2004a) Questionable efficacy of extracorporeal shock wave therapy for Peyronie's disease: results of a prospective approach. J Urol 171, 296-299.
9. Hauck EW, Mueller UO, Bschleipfer T, Schmelz HU, Diemer T & Weidner W. (2004b) Extracorporeal shock wave therapy for Peyronie's disease: exploratory meta-analysis of clinical trials. J Urol 171, 740-745.
10. Hauck EW, Diemer T, Schmelz HU & Weidner W. (2006) A critical analysis of nonsurgical treatment of Peyronie's disease. Eur Urol 49, 987-997.
11. Kadioglu A, Oktar T, Kandirali E, Kendirci M, Sanli O & Ozsoy C. (2004) Incidentally diagnosed Peyronie's disease in men presenting with erectile dysfunction. Int J Impot Res 16, 540-543.
12. Lebret T, Loison G, Hervé JM, Mc Eleny KR, Lugagne PM, Yonneau L, Orsoni JL, Saporta F, Butreau M & Botto H. (2002) Extracorporeal shock wave therapy in the treatment of Peyronie's disease: experience with standard lithotriptor (Siemens-multiline). Urology 59, 657-661.
13. Levine LA & Latchamsetty KC. (2002) Treatment of erectile dysfunction in patients with Peyronie's disease using sildenafil citrate. Int J Impot Res 14, 478-482.
14. McMahon C. (2005) Comparison of efficacy, safety, and tolerability of on-demand tadalafil and daily dosed tadalafil for the treatment of erectile dysfunction. J Sex Med 2, 415-425.
15. Mirone V, Imbimbo C, Palmieri A, Longo N, Fusco F & Tajana G. (2002) A new biopsy technique to investigate Peyronie's disease associated histologic alterations: results with two different forms of therapy. Eur Urol 42, 239-244.
16. Mulhall J, Anderson M & Parker M. (2005) A surgical algorithm for men with combined Peyronie's disease and erectile dysfunction: functional and satisfaction outcomes. J Sex Med 2, 132-138.
17. Mulhall JP, Schiff J & Guhring P. (2006) An analysis of the natural history of Peyronie's disease. J Urol 175, 2115-2118.
18. Palmieri A, Imbimbo C, Longo N, Fusco F, Verze P, Mangiapia F, Creta M & Mirone V. (2009) A first prospective, randomized, double-blind, placebo-controlled clinical trial evaluating extracorporeal shock wave therapy for the treatment of Peyronie's disease. Eur Urol 56, 363-369.
19. Porst H, Hell-Momeni K & Büttner H. (2009) Chronic PDE-5 inhibition in patients with erectile dysfunction: new treatment approach using once daily. Tadalafil Urologe A 48, 1318.
20. Pryor JP. (1988) Peyronie's disease and impotence. Acta Urol Belg 56, 317-321.
21. Rosen RC, Cappelleri JC, Smith MD, Lipsky J & Peña BM. (1999) Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF-5) as a diagnostic tool for erectile dysfunction. Int J Impot Res 11, 319-326.
22. Rosen R, Catania J, Lue T, Althof S, Henne J, Hellstrom W & Levine L. (2008) Impact of Peyronie's disease on sexual and psychosocial functioning: qualitative findings in patients and controls. J Sex Med 5, 1977-1984.
23. Valente EG, Vernet D, Ferrini MG, Qian A, Rajfer J & Gonzalez-Cadavid NF. (2003) L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie's fibrotic plaque and related fibroblast cultures. Nitric Oxide 9, 229-244.
24. Weidner W, Schroeder-Printzen I, Weiske WH & Vosshenrich R. (1997) Sexual dysfunction in Peyronie's Disease: an analysis of 222 patients without previous local plaque therapy. J Urol 157, 325-328.
25. Wild C, Khene M & Wanke S. (2000) Extracorporeal shock wave therapy in orthopedics. Assessment of an emerging health technology. Int J Technol Assess Health Care 16, 199-209.